A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00171860
Recruitment Status : Terminated
First Posted : September 15, 2005
Last Update Posted : May 1, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : July 2007
  Study Completion Date : No date given